Chapter 11 Antihypertensive Agents

Basic and Clinical Pharmacology
C11 ANTIHYPERTENSIVE AGENTS

A. Q. Sangalang, MD, MHPEd, FPOGS
FACULTY OF PHARMACY
UNIVERSITY OF SANTO TOMAS
• Classification of hypertension on the basis of blood pressure
§ Strategies for treating high blood pressure are based on determinants of arterial
pressure
§ Strategies include reduction of

o Blood volume
o Sympathetic tone
o Vascular smooth muscle tone
o Angiotensin effects
§ Baroreceptor reflex and renin response to lower blood pressure (BP)
§ Compensatory homeostatic responses to these drugs may be significant (See
Table in Katzung)
§ Compensatory mechanisms can be counteracted by
o Tachycardia- beta blockers, reserpine
o Salt and water retention-diuretics, angiotensin antagonists
1
DIURETICS
§ Lower BP by reduction of blood volume and direct vascular effect
§ Compensatory responses to BP lowering are minimal
THIAZIDES
• HYDROCHLOROTHIAZIDE
o Adequate in mild hypertension
o Maximum antihypertensive action is achieved with doses below those
required for maximum diuretic effect
LOOP DIURETICS
• FUROSEMIDE
o Used in moderate, severe, and malignant hypertension
SYMPATHOPLEGICS
§ Interfere with sympathetic nerve functions
§ Compensatory mechanisms and adverse effects are marked for some of these
agents
§ Reduction of the following
o Venous tone
o Heart rate
o Contractile force of the heart
o Cardiac output (CO)
o Total peripheral resistance (TPR)
CLASSIFICATION
A. Baroreceptor sensitizing – No drug available
B. CNS Active
C. Ganglion Blocking Drugs
D. Post-ganglionic sympathetic blocker
E. Adrenoceptor blockers
2
B. CNS-ACTIVE AGENTS
ALPHA2-SELECTIVE AGENTS
CLONIDINE
• Decrease sympathetic outflow by activation of α2-receptors in the CNS
• Readily enter the CNS when given orally
• Reduce BP by reducing cardiac output, vascular resistance, or both
• Major compensatory mechanism is salt retention
• Can cause sedation
o Rebound hypertension
Ø Sudden discontinuation causes elevated BP due to loss of
antihypertensive effect
3
Ø Controlled by reinstitution of the drug or administration of α2
blockers (phentolamine)
METHLYDOPA
• Prodrug converted to methlynorepinephrine in the brain
• Causes hematologic immunotoxicity (+ Coombs test) ---hemolytic anemia
• Sedation is more pronounced
C. GANGLION-BLOCKING DRUGS
HEXAMETHONIUM and TRIMETHAPHAN

• Very efficacious
• Adverse effects are severe
• Obsolete
• Major compensatory mechanism is salt retention
• Toxicities reflect parasympathetic blockade
o Blurred vision
o Constipation
o Urinary hesitancy
o Sexual dysfunction
o Orthostatic hypotension
D. POSTGANGLIONIC SYMPATHETIC NERVE TERMINAL BLOCKERS

• Very efficacious in high doses
• High incidence of side effects
• Long duration of action (days to weeks)
• Compensatory response is salt retention
RESERPINE
• Depletes the adrenergic nerve terminal of norepinephrine (NE) stores
• Adjunct to other agents in low doses
• Readily enters the CNS
• Toxicity
o Behavioral depression
o May require discontinuation of the drug
GUANETHEDINE
• Blocks the release of stores of NE
• Rarely used
• Does not enter the CNS
• Requires the catecholamine reuptake pump (uptake 1) to reach its intracellular site
of action
• Toxicity
o Orthostatic hypotension
o Sexual dysfunction
• Drugs that inhibit the pump (cocaine, tricyclic antidepressants) will interfere with
its action
4
MAO INHIBITORS
• Formation of octopamine, a false transmitter released during normal nerve action
potential results to diminished vascular and cardiac response---lower BP
• Large doses of indirect-acting sympathomimetics (tyramine) may cause release of
large amounts of NE and lead to a hypertensive crisis
• No longer used for hypertension
• Occasionally used for treatment of severe depressive disorder
E. ADRENOCEPTOR BLOCKERS
• Effective antihypertensive agents
PRAZOSIN
• Alpha1-selective blockers
• Reduce vascular resistance and venous return
• Free of severe adverse effects
PHENTOLAMINE, PHENOXYBENZAMINE
• Nonselective α-blockers
• No value in chronic hypertension
• Excessive compensatory responses especially tachycardia
BETA-BLOCKERS
• Initially reduce cardiac output
• Decrease vascular resistance, it reduces renin release from the kidneys that
results to reduce angiotensin levels
• Most heavily used antihypertensive
• Associated with
o Slightly elevated glucose, LDL, triglyceride,
o Diminished levels of HDL
CALCIUM CHANNEL BLOCKERS

• NIFEDIPINE, VERAPAMIL, DILTIAZEM
• Effective vasodilators
• Orally active
• Chronic use
• Used in hypertension of any severity
Fewer compensatory responses
VASODILATORS
• Dilate blood vessels by acting directly on the smooth muscle cells through
nonautonomic mechanisms
• Compensatory responses maybe marked and include salt retention and
tachycardia
§ FOUR MAJOR MECHANISMS

o Release of nitric oxide
o Opening of potassium channels
o Blockade of calcium channels
o Activation of D1 dopamine receptors
5
HYDRALAZINE
• Older vasodilator
• More effect on arterioles than veins
• Orally active
• For chronic therapy
Acts through release of nitric oxide from endothelial cells
• Rarely used at high dosage because of toxicity
• Efficacy is limited
• Toxicity
o Compensatory responses (tachycardia, salt and water retention)
o Drug-induced lupus erythematosus (reversible upon stopping the drug
(uncommon at doses below 200 mg/d)
MINOXIDIL
• Older vasodilator
• Prodrug
• Minoxidil sulfate, its metabolite is a potassium channel opener that hyperpolarizes
and relaxes vascular smooth muscle
• Extremely efficacious
• Reserved for severe hypertension
• Toxicity
o Severe compensatory responses
o Hirsutism
o Pericardial abnormalities
NITROPRUSSIDE and DIAZOXIDE

§ IV vasodilators used in hypertensive emergencies
NITROPRUSSIDE
• Short-acting (duration is a few minutes)
• Infused continuously
• Release of nitric oxide from the drug which stimulates guanylyl cyclase
and increase cGMP in the muscle
• Toxicity
• Excessive hypotension
o Tachycardia
o Accumulation of cyanide or thiocyanate in the blood if infusion is
continued for several days
DIAZOXIDE
• Given as IV boluses or as an infusion (duration of action of several hours)
• Opens potassium channels, hyperpolarizes and relaxes smooth muscles
• Reduces insulin release
• Used to treat hypoglycemia caused by insulin-producing tumors
• Toxicity
o Hypotension
o Hyperglycemia
o Salt and water retention
6
FENOLDOPAM
• Dopamine D1 receptor activation cause marked arteriolar vasodilation
• Given IV
• Used for hypertensive emergencies
ANGIOTENSIN ANTAGONISTS
• Two primary groups
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS

• Captopril, enalapril
• More extensively used
• Inhibit the enzyme ACE, kininase II, and peptidyl dipeptidase
• Reduction in blood levels of angiotensin II and aldosterone
• Increase in endogenous vasodilators (bradykinin)
• Low incidence of serious adverse effects when given in normal doses (except in
pregnancy)
• Minimal compensatory responses
• Toxicity
o Cough (30% of patients)
o Renal damage in patients with preexisting renal vascular disease (protect
the diabetic kidney)
o Renal damage in fetus
ANGIOTENSIN II RECEPTOR BLOCKERS

• Losartan, valsartan, irbesartan, candesartan and other analogs
• Orally active
• Competitively inhibit angiotensin II at AT1 receptor site
• Toxicity
o Lower incidence of cough
o Fetal renal toxicity
o Contraindicated in pregnancy
o Reduce aldosterone levels
o Causes potassium retention and lead to accumulation
Ø Patients with renal impairment
Ø High-potassium diet
Ø Taking drugs that conserve potassium
7
CLINICAL USES
“STEPPED CARE”
• Use of multiple drugs at lower dosage to reduce overall toxicity and minimize
compensatory responses
• Used in patients with severe hypertension
• Drugs are added to a patient’s regimen in stepwise fashion
• Additional agent is chosen from a different subgroup until BP control is achieved
• Lifestyle measures (salt restriction and weight reduction
• Diuretics
• Sympathoplegic (beta-blockers)
• ACE inhibitors
• Vasodilator (calcium-channel blockers)
MONOTHERAPY
• Many patients do well on a single drug
• Simple
• Better patient compliance
• Low incidence of toxicity
AGE
• Older patients respond better to diuretics and beta-blockers
MALIGNANT HYPERTENSION
• Accelerated phase of severe hypertension
• Rising BP and rapidly progressing damage to vessels and end organs
8
• Deterioration of
o Renal function
o Encephalopathy
o Retinal hemorrhages
• Angina, stroke or myocardial infarction
• Management
o Emergency
o Vasodilators (nitroprusside, fenoldopam, diazoxide) combined with
diuretics and beta-blockers
o Lower BP to 140-160/110 mm Hg
o Further reduction is pursued more slowly
9
10
11

Chapter 11 Antihypertensive Agents

Uploaded by

Copyright:

Available Formats

Chapter 11 Antihypertensive Agents

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Chapter 11 Antihypertensive Agents

Uploaded by

Copyright:

Available Formats

Basic and Clinical Pharmacology

C11 ANTIHYPERTENSIVE AGENTS

• Classification of hypertension on the basis of blood pressure

§ Strategies include reduction of

HEXAMETHONIUM and TRIMETHAPHAN

D. POSTGANGLIONIC SYMPATHETIC NERVE TERMINAL BLOCKERS

CALCIUM CHANNEL BLOCKERS

§ FOUR MAJOR MECHANISMS

NITROPRUSSIDE and DIAZOXIDE

ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS

ANGIOTENSIN II RECEPTOR BLOCKERS

You might also like